litlas
Log inCreate account

Stanley Cohen

Active 1954–2025

198
Papers
58,652
Citations
121
h-index
197
i10-index

Citations

Citations per year for Stanley Cohen1967: 11 citations1968: 9 citations1969: 9 citations1970: 21 citations1971: 22 citations1972: 38 citations1973: 25 citations1974: 65 citations1975: 85 citations1976: 99 citations1977: 141 citations1978: 176 citations1979: 278 citations1980: 268 citations1981: 286 citations1982: 378 citations1983: 390 citations1984: 510 citations1985: 406 citations1986: 360 citations1987: 285 citations1988: 265 citations1989: 267 citations1990: 206 citations1991: 177 citations1992: 172 citations1993: 129 citations1994: 174 citations1995: 129 citations1996: 154 citations1997: 151 citations1998: 151 citations1999: 163 citations2000: 155 citations2001: 163 citations2002: 166 citations2003: 175 citations2004: 202 citations2005: 209 citations2006: 223 citations2007: 258 citations2008: 329 citations2009: 348 citations2010: 343 citations2011: 359 citations2012: 346 citations2013: 279 citations2014: 275 citations2015: 275 citations2016: 223 citations2017: 239 citations2018: 250 citations2019: 668 citations2020: 877 citations2021: 786 citations2022: 560 citations2023: 472 citations2024: 608 citations2025: 316 citations2026: 7 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,957 citing papers, 33.2% of this breakdownUnited Kingdom: 1,302 citing papers, 8.7% of this breakdownGermany: 765 citing papers, 5.1% of this breakdownCanada: 711 citing papers, 4.8% of this breakdownItaly: 619 citing papers, 4.1% of this breakdownJapan: 591 citing papers, 4% of this breakdownFrance: 566 citing papers, 3.8% of this breakdownChina: 530 citing papers, 3.5% of this breakdownNetherlands: 493 citing papers, 3.3% of this breakdownAustralia: 439 citing papers, 2.9% of this breakdownSwitzerland: 322 citing papers, 2.2% of this breakdownSpain: 307 citing papers, 2.1% of this breakdown
0%33.2%Other 22.3%

Institutions

Fields

  • Medicine56.3%
  • Biochemistry, Genetics and Molecular Biology24.3%
  • Immunology and Microbiology6.5%
  • Neuroscience4.2%
  • Social Sciences2.4%
  • Chemistry0.9%
  • Other5.4%

Topics

  • Rheumatoid Arthritis Research and Therapies7.5%
  • Spondyloarthritis Studies and Treatments3.1%
  • Monoclonal and Polyclonal Antibodies Research2.7%
  • Autoimmune and Inflammatory Disorders Research2.7%
  • Cytokine Signaling Pathways and Interactions2.2%
  • Systemic Lupus Erythematosus Research2%
  • Other79.8%

Coauthors

All papers

Open in search
  1. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

    Authors: Gerd R Burmester, Stanley Cohen, Kevin Winthrop, Peter Nash, Alan D. Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P. Lacerda, Hannah Palac, Tim Shaw, Philip J. Mease, Emma Guttman‐Yassky - RMD Open 2023 cited by 210

  2. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

    Authors: Stanley Cohen, Ronald van Vollenhoven, Kevin Winthrop, Cristiano A. F. Zerbini, Yoshiya Tanaka, Louis Bessette, Ying Zhang, Nasser Khan, Barbara A. Hendrickson, Jeffrey Enejosa, Gerd R Burmester - Annals of the Rheumatic Diseases 2020 cited by 233

  3. Oral surveillance and JAK inhibitor safety: the theory of relativity

    Authors: Kevin Winthrop, Stanley Cohen - Nature Reviews Rheumatology 2022 cited by 196

  4. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study

    Authors: Josef S Smolen, Aileen L. Pangan, Paul Emery, William F. C. Rigby, Yoshiya Tanaka, Juan Ignacio Vargas, Ying Zhang, Nemanja Damjanov, Alan Friedman, Mohamed I. A. Othman, Heidi S. Camp, Stanley Cohen - The Lancet 2019 cited by 378

  5. Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

    Authors: Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen, Eun Bong Lee, Juan A. García Meijide, Sylke Wagner, Šárka Forejtová, Samuel H. Zwillich, David Gruben, Tamás Koncz, Gene V. Wallenstein, Sriram Krishnaswami, John Bradley, Bethanie Wilkinson - New England Journal of Medicine 2012 cited by 939

  6. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

    Authors: Stanley Cohen, Paul Emery, Maria Greenwald, Maxime Dougados, Richard Furie, Mark C. Genovese, Edward Keystone, J. Loveless, Gerd‐Rüdiger Burmester, Matthew Cravets, E. Hessey, T Shaw, Mark C. Totoritis - Arthritis & Rheumatism 2006 cited by 1,640

  7. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

    Authors: Stanley Cohen, Yoshiya Tanaka, Xavier Mariette, Jeffrey R. Curtis, Eun Bong Lee, Peter Nash, Kevin Winthrop, Christina Charles‐Schoeman, Lisy Wang, Connie Chen, Kenneth Kwok, Pinaki Biswas, Andrea Shapiro, Ann Madsen, J. Wollenhaupt - RMD Open 2020 cited by 181

  8. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

    Authors: J. Wollenhaupt, Eun-Bong Lee, Jeffrey R. Curtis, Joel C. Silverfield, Ketti K. Terry, Koshika Soma, Chris Mojcik, Ryan DeMasi, Sander Strengholt, Kenneth Kwok, Irina Lazariciu, Lisy Wang, Stanley Cohen - Arthritis Research & Therapy 2019 cited by 320

  9. Denosumab in Postmenopausal Women with Low Bone Mineral Density

    Authors: Michael R. McClung, E. Michael Lewiecki, Stanley Cohen, Michael A. Bolognese, Grattan C. Woodson, Alfred H. Moffett, Munro Peacock, Paul D. Miller, Samuel Lederman, Charles H. Chesnut, Douglas Lain, Alan Kivitz, Donna Holloway, Charlie Zhang, Mark Peterson, Pirow Bekker - New England Journal of Medicine 2006 cited by 1,215

  10. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data

    Authors: Philip J. Mease, Christina Charles‐Schoeman, Stanley Cohen, Lara Fallon, John Woolcott, Huifeng Yun, Joel M. Kremer, Jeffrey D. Greenberg, Wendi Malley, Alina Onofrei, Keith S. Kanik, Daniela Graham, Cunshan Wang, Carol A. Connell, Hernán Valdez, Manfred Hauben, Eric Hung, Ann Madsen, Thomas V. Jones, Jeffrey R. Curtis - Annals of the Rheumatic Diseases 2020 cited by 221

  11. Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain

    Authors: Philip G. Conaghan, David J. Hunter, Stanley Cohen, Virginia B. Kraus, Françis Berenbaum, Jay R. Lieberman, Deryk G. Jones, Andrew I. Spitzer, David S. Jevsevar, Nathaniel P. Katz, Diane J. Burgess, Joelle Lufkin, James R. Johnson, N. Bodick - Journal of Bone and Joint Surgery 2018 cited by 172

  12. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

    Authors: Stanley Cohen, Yoshiya Tanaka, Xavier Mariette, Jeffrey R. Curtis, Eun Bong Lee, Peter Nash, Kevin Winthrop, Christina Charles‐Schoeman, Krishan Thirunavukkarasu, Ryan DeMasi, Jamie Geier, Kenneth Kwok, Lisy Wang, Richard J. Riese, J. Wollenhaupt - Annals of the Rheumatic Diseases 2017 cited by 395

  13. Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis

    Authors: Daniel H. Solomon, Jon T. Giles, Katherine P. Liao, Paul M. Ridker, Pamela M. Rist, Robert J. Glynn, Rachel Broderick, Fengxin Lu, Meredith Murray, Kathleen M.M. Vanni, L Santacroce, Shady Abohashem, Philip M. Robson, Zahi A. Fayad, Venkatesh Mani, Ahmed Tawakol, Joan M. Bathon, Yousaf Ali, Joshua Baker, Marcy B. Bolster, Vivian Bykerk, Christina Charles-Schoeman, Cong-Qiu Chu, Stanley Cohen, Jeffrey Curtis, Jack Cush, Christina Downey, Margarita Fallena, Nazanin Firooz, Brigid Freyne, Jonathan Graf, Maria Greenwald, Diane Horowitz, Elaine Husni, Rajesh Kataria, Edward Keystone, Alan Kivitz, Joel Kremer, Robert Levin, Kristine Lohr, Elena Massarotti, Alan Matsumoto, Philip Mease, Barbara Mendez, Jeffrey Miller, Larry Moreland, Binh Nguyen, Deborah Parks, William Rigby, Jose Scher, Elena Schiopu, Beth Scholz, Guillermo Valenzuela - Annals of the Rheumatic Diseases 2022 cited by 74

  14. Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase II Trial

    Authors: Stanley Cohen, Katie Tuckwell, Tamiko R. Katsumoto, Rui Zhao, Joshua Galanter, Chin Lee, Julie Rae, Balázs István Tóth, Nandhini Ramamoorthi, Jason A. Hackney, Alberto Berman, Nemanja Damjanov, Dmytro Fedkov, Sławomir Jeka, Leslie W. Chinn, Michael J. Townsend, Alyssa Morimoto, Mark C. Genovese - Arthritis & Rheumatology 2020 cited by 118

  15. The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

    Authors: Ferdinand C. Breedveld, Michael H. Weisman, Arthur F. Kavanaugh, Stanley Cohen, Karel Pavelká, Ronald van Vollenhoven, John T. Sharp, John L. Perez, G Spencer-Green - Arthritis & Rheumatism 2005 cited by 1,786

  16. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee

    Authors: Stanley Cohen, Susanna Proudman, Alan Kivitz, Francis X. Burch, John P. Donohue, Deborah Burstein, Yu‐Nien Sun, Christopher Banfield, Michael S. Vincent, Liyun Ni, Debra Zack - Arthritis Research & Therapy 2011 cited by 244

  17. Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study

    Authors: Désirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann, Edward Keystone, Joel M. Kremer, Cristiano A. F. Zerbini, Myrna Cardiel, Stanley Cohen, Peter Nash, Yeong Wook Song, Dana Tegzová, Bradley T. Wyman, David Gruben, Birgitta Benda, Gene V. Wallenstein, Sriram Krishnaswami, Samuel H. Zwillich, John Bradley, Carol A. Connell, and the ORAL Scan Investigators - Arthritis & Rheumatism 2013 cited by 582

  18. Artificial Intelligence in Pathology

    Authors: Stanley Cohen, Richard M. Levenson, Liron Pantanowitz - American Journal Of Pathology 2021 cited by 52

  19. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

    Authors: Mark C. Genovese, Stanley Cohen, Larry W. Moreland, D. Lium, Sean Robbins, Richard Newmark, Pirow Bekker, for the 20000223 Study Group - Arthritis & Rheumatism 2004 cited by 522

  20. A NERVE GROWTH-STIMULATING FACTOR ISOLATED FROM SARCOM AS 37 AND 180

    Authors: Stanley Cohen, Rita Levi‐Montalcini, Viktor Hamburger - National Academy of Sciences, Proceedings of the National Academy of Sciences 1954 cited by 527

  21. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis

    Authors: John D. Isaacs, Stanley Cohen, Paul Emery, Paul P. Tak, Jianmei Wang, Guiyuan Lei, Sarah Williams, Preeti Lal, Simon Read - Annals of the Rheumatic Diseases 2012 cited by 196

  22. Isolation of a Mouse Submaxillary Gland Protein Accelerating Incisor Eruption and Eyelid Opening in the New-born Animal

    Authors: Stanley Cohen - Journal of Biological Chemistry 1962 cited by 2,197

  23. A Randomized, Double‐Blind, Sham‐Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis

    Authors: Matthew Baker, Sarah Kavanagh, Stanley Cohen, Alan K. Matsumoto, Ara Dikranian, John Tesser, Alan Kivitz, Konstantinos Alataris, Mark C. Genovese - Arthritis & Rheumatology 2023 cited by 33

  24. A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

    Authors: Joel M. Kremer, Stanley Cohen, Bethanie Wilkinson, Carol A. Connell, Jonathan French, Juan J. Gómez‐Reino, David Gruben, Keith S. Kanik, Sriram Krishnaswami, Virginia Pascual‐Ramos, Gene V. Wallenstein, Samuel H. Zwillich - Arthritis & Rheumatism 2011 cited by 347